EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Frontier Biotechnologies EBITDA Margin % Related Terms
Frontier Biotechnologies EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Frontier Biotechnologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontier Biotechnologies EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Frontier Biotechnologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Frontier Biotechnologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontier Biotechnologies (SHSE:688221) has a EBITDA Margin % of 77.30% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Frontier Biotechnologies and its competitors. According to the industry distribution chart, Frontier Biotechnologies ranks #680 out of 952 companies in the Drug Manufacturers industry, placing it in the top 71.4%.
Is Frontier Biotechnologies' EBITDA Margin % too high?
Frontier Biotechnologies' current EBITDA Margin % is 77.30%. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Frontier Biotechnologies' value of 77.30% is 519.9% above this industry median. Based on the distribution chart, Frontier Biotechnologies ranks #680 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Frontier Biotechnologies has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontier Biotechnologies' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Frontier Biotechnologies ranks #680 out of 952 companies for EBITDA Margin %. This places Frontier Biotechnologies in the lower half of its industry. The industry median EBITDA Margin % is 12.47. Frontier Biotechnologies' value of 77.30% is 519.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontier Biotechnologies's current EBITDA Margin % of 77.30% is 519.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Frontier Biotechnologies and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontier Biotechnologies's current EBITDA Margin % is 77.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontier Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Frontier Biotechnologies (SHSE:688221) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥37.60, compared to a current price of ¥19.62 — trading 47.8% below its estimated fair value. The current EBITDA Margin % is 77.30% and 519.9% above the Drug Manufacturers industry median of 12.47. Frontier Biotechnologies' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Frontier Biotechnologies (SHSE:688221), the current EBITDA Margin % is 77.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontier Biotechnologies (SHSE:688221) Overvalued in 2026?
Based on GuruFocus' analysis, Frontier Biotechnologies stock appears to be undervalued.
The current stock price of ¥19.62 is trading 47.8% below its estimated GF Value™ of ¥37.60.
GuruFocus considers Frontier Biotechnologies to be Significantly Undervalued.
Key valuation signals for SHSE:688221:
EBITDA Margin %: 77.30%
GF Value™: ¥37.60 vs. price of ¥19.62 (47.8% below fair value)
Industry Position: 519.9% above the Drug Manufacturers median (#680 of 952)
No single metric tells the full story. See the SHSE:688221 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688221 has been successfully added to your 
